Mild to Moderate Psoriasis Clinical Trial
Official title:
A Multicenter, Randomized, Double-blind, Four-Arm Parallel-Group, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis
This is a phase II study to evaluate the efficacy and safety of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.
Icotinib Hydrochloride is an oral, small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which has been approved for treating advanced non-small cell lung cancer (NSCLC) in China. Over-expressions of EGFR and its downstream signaling proteins are implicated in the pathogenesis of psoriasis and TKIs have been considered as potential antipsoriatic agents. Icotinib hydrochloride is being developed as a cream for the treatment of mild to moderate psoriasis. This is a multicenter , randomized, doubleblind, four-arm parallel-group, placebo-controlled phase II study to assess the efficacy and safety of icotinib hydrochloride cream (1.0%, 2.0%, 4.0%) in patients with mild to moderate psoriasis. Approximately 260 subjects will be enrolled. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02529956 -
A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis
|
Phase 1 | |
| Withdrawn |
NCT00788424 -
Topical Application of AS101 for the Treatment of Psoriasis
|
Phase 2 | |
| Completed |
NCT01587755 -
Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP)
|
Phase 4 | |
| Recruiting |
NCT05249972 -
A Phase III Study in Subjects With Mild to Moderate Psoriasis.
|
Phase 3 | |
| Recruiting |
NCT05965089 -
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
|
Phase 1 | |
| Completed |
NCT01000714 -
Determination of the Efficacy and Safety of Psirelax in the Relief of the Disease in Psoriasis
|
Phase 2 |